News | Cardiovascular Surgery | May 01, 2017

ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology

System with Active Clearance Technology helps reduce the occurrence of chest tube occlusions following cardiac surgery

ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology

May 1, 2017 — ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow Active Clearance Technology (ACT) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery, according to the company.

Evidence suggests that chest tubes used for drainage after cardiac surgery have a high failure rate due to clogging. If the extra blood is not removed from inside the chest cavity after surgery, patients may require additional procedures, which are known as retained blood syndrome (RBS). Multiple studies have shown that retained blood has a statistically significant negative impact on cardiac surgery patients after surgery, including a higher likelihood of mortality, longer ICU and hospital lengths of stay, four times higher infection rates and increased cost of care.

ClearFlow’s PleuraFlow ACT System is the only U.S. Food and Drug Administration (FDA)-cleared device available, according to ClearFlow, that enables caregivers to proactively prevent or minimize chest tube occlusions and reduce retained blood.

Announcing ClearFlow as the recipient of the award in the ‘New Product Innovation’ category, Frost & Sullivan referred to PleuraFlow as a “transformational force in post-operative cardiothoracic surgery protocols.”

“Clearly, the PleuraFlow ACT System is uniquely positioned for sustained success as it meets customers’ core requirements of quality, functionality and reliability,” remarked Frost & Sullivan Senior Industry Analyst Patrick Riley.

Each year, Frost & Sullivan presents this award to the company that develops an innovative product to leverage leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers.

The PleuraFlow Active Clearance Technology System is approved for use in the United States, Europe, Australia, Brazil, Canada, and other countries in Asia and the Middle East.

For more information: www.clearflow.com

Related Content

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease
News | Cardiovascular Surgery | May 03, 2019
Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one...
SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Overlay Init